INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) Treatment

  Measured over: Up to approximately 71 months

• Number of Participants With Clinically Significant Changes in Hematological Parameters

  Measured over: Up to approximately 71 months

• Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters

  Measured over: Up to approximately 71 months

• Number of Participants With Clinically Significant Changes in Urinalysis Parameters

  Measured over: At baseline, Weeks 3, 6, 9, then every 6 weeks thereafter, up to 71 months

• Antigen-Specific Immune Response

  Measured over: Up to approximately 71 months

• Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Review in Cohort A

  Measured over: From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months

Changes Tremor has spotted